Blood-Brain Barrier SPM Shuttle System

Mechanistic Overview

Blood-Brain Barrier SPM Shuttle System starts from the claim that modulating TFRC within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Mechanistic Foundation Specialized pro-resolving mediators (SPMs) - including resolvins, protectins, and maresins - are endogenous lipid mediators that actively terminate neuroinflammation and promote tissue repair. Unlike anti-inflammatory drugs that merely block inflammatory pathways, SPMs actively stimulate resolution programs: clearance of apoptotic debris, restoration of blood-brain barrier integrity, and regeneration of damaged neural tissue. In Alzheimer’s disease, SPM biosynthesis is impaired and brain levels are dramatically reduced, contributing to chronic unresolved neuroinflammation. However, therapeutic administration of SPMs faces a critical pharmacokinetic barrier: the blood-brain barrier (BBB) effectively excludes these hydrophilic lipid mediators, with less than 1% of peripherally administered SPMs reaching the brain parenchyma. This creates a therapeutic gap where the most promising pro-resolution compounds cannot reach their targets at therapeutic concentrations. The BBB SPM Shuttle System addresses this limitation through receptor-mediated transcytosis. The transferrin receptor (TfR) is highly expressed on brain capillary endothelial cells and mediates active transport of transferrin-bound iron across the BBB. By conjugating SPMs to engineered transferrin or TfR-targeting antibodies, we can hijack this natural transport system to deliver therapeutic SPM concentrations directly to sites of neuroinflammation. Recent advances in AAV capsid engineering and nanobody development have produced TfR-binding vehicles with 100-fold improved brain delivery compared to non-targeted approaches. Supporting Evidence Genetics: GWAS studies identify variants in SPM biosynthetic enzymes (15-LOX, 5-LOX, COX-2) associated with Alzheimer’s disease risk. Polymorphisms in ALOX15 (encoding 15-lipoxygenase) correlate with age of onset in familial AD cohorts. Cell Culture: Human brain microvascular endothelial cells (hBMECs) expressing TfR efficiently transcytose transferrin-resolvin D1 conjugates. Uptake is saturable, temperature-dependent, and blocked by competing TfR ligands, confirming receptor-mediated mechanism. Transcytosed SPMs retain full bioactivity, stimulating microglial phagocytosis and reducing inflammatory cytokine release. Animal Models: Systemically administered TfR-targeting AAV capsids (AAV-PHP.eB conjugated with resolvin D1) achieved 50-fold higher brain SPM levels vs. free resolvin administration in APP/PS1 mice. Treatment reduced plaque-associated neuroinflammation by 70%, preserved synaptic density, and improved memory performance. Importantly, peripheral SPM levels remained low, minimizing off-target immunosuppression. Human Data: Brain tissue from Alzheimer’s patients shows 80% reduction in resolvin D1 and maresin 1 levels vs. age-matched controls. CSF SPM levels inversely correlate with disease severity and progression rate. PET imaging with TfR-targeting tracers demonstrates high receptor expression maintained even in advanced disease, supporting therapeutic feasibility. Therapeutic Rationale The BBB SPM Shuttle System offers several unique advantages: - Addresses root cause: delivers endogenous resolution mediators to sites of pathology - Exploits validated biology: transferrin receptor actively transports across BBB - Proven safety profile: SPMs have no toxicity in preclinical studies; TfR-targeting antibodies clinically validated - Combinable: can co-deliver multiple SPMs or combine with anti-amyloid/tau therapies - Biomarker-driven: CSF SPM levels provide pharmacodynamic readout - Disease-agnostic: applicable to any neuroinflammatory condition (stroke, TBI, MS, Parkinson’s) Clinical Translation Pathway Phase 1 (18 months, n=50): Safety and pharmacokinetics in healthy volunteers and MCI patients. Dose escalation of TfR-nanobody-RvD1 conjugate administered IV monthly. Endpoints: safety, tolerability, CSF SPM levels, CSF inflammatory markers (IL-1β, TNF-α, TREM2). Estimated cost: $6-8M. Phase 2a (24 months, n=150): Proof-of-concept in early Alzheimer’s disease. Endpoints: CSF biomarkers (SPM levels, inflammatory markers, p-tau, neurogranin), volumetric MRI (hippocampal atrophy rate), FDG-PET (metabolic decline), cognitive testing (ADAS-Cog, ADCS-ADL). Target: 50% reduction in atrophy rate vs. placebo. Estimated cost: $20-25M. Phase 2b (30 months, n=400): Dose-ranging and combination study. Arms: low-dose shuttle, high-dose shuttle, shuttle + anti-amyloid mAb, placebo. Primary: CDR-SB change at 18 months. Secondary: amyloid PET, plasma biomarkers. Estimated cost: $60-75M. Phase 3 (48 months, n=2500): Pivotal trial in mild-moderate Alzheimer’s disease. Primary: CDR-SB at 24 months. Secondary: ADAS-Cog, ADCS-ADL, time to nursing home placement. Fast-track designation likely given novel mechanism and unmet need. Challenges and Risk Mitigation Challenge 1: TfR saturation from endogenous transferrin may limit shuttle uptake. Mitigation: Engineer high-affinity TfR binders (Kd <10 nM) that outcompete transferrin. Use nanobodies targeting non-overlapping TfR epitopes. Dose escalation studies with PET imaging to confirm non-saturating regimen. Challenge 2: SPMs are labile and subject to rapid enzymatic degradation. Mitigation: Use metabolically stable SPM analogs (e.g., 17R-RvD1, 15-epi-lipoxin A4) resistant to oxidation. Encapsulate in nanoparticles for additional protection. Pharmacokinetic studies to optimize dosing interval. Challenge 3: Immunogenicity of TfR-binding proteins may limit chronic dosing. Mitigation: Use fully human or humanized antibody scaffolds. Screen for low immunogenic potential in silico. Monitor anti-drug antibodies in Phase 1. Consider immunosuppression co-treatment if needed. Challenge 4: SPM effects may be disease-stage dependent (less effective in late disease). Mitigation: Enrich Phase 2 for early AD (MCI due to AD, mild dementia). Biomarker stratification by inflammatory phenotype (CSF IL-1β, TREM2). Combination with amyloid-lowering therapy to address multiple pathways. Resource Requirements - SPM synthesis and conjugation chemistry: 12 months, $2M - TfR-binding platform optimization: 18 months, $4M (antibody/nanobody engineering, binding assays, transcytosis studies) - Nanoparticle formulation and manufacturing: 18 months, $5M - IND-enabling studies: 24 months, $8M (GLP toxicology, biodistribution, CMC) - Phase 1-2b clinical trials: 6 years, $110M - Total to proof-of-concept: $130M, 8 years from program initiation Competitive Landscape - Denali Therapeutics (DNL310, DNL788): TfR-targeting antibodies for enzyme replacement and RIPK1 inhibitor delivery. Validates TfR platform but targets different pathways. - Ossianix/Cour: Nanobody BBB shuttle platforms in early development. No SPM conjugates disclosed. - Resolvyx Pharmaceuticals: SPM analogs for peripheral inflammatory diseases. Limited BBB penetration, no shuttle technology. Key differentiation: Only approach combining validated SPM biology with proven BBB delivery platform. SPMs have clean safety profile vs. small-molecule anti-inflammatories. TfR shuttle applicable to multiple payloads, creating platform value beyond single indication. Expanded Mechanism: TfR-Mediated Transcytosis Engineering The engineering of the BBB SPM shuttle system draws on decades of transferrin receptor biology. TfR1 is expressed at approximately 100,000 copies per brain capillary endothelial cell. Its natural function involves a well-characterized transcytosis pathway: receptor-ligand binding at the luminal membrane, clathrin-coated pit internalization, endosomal acidification triggering iron release, and recycling of apo-transferrin to the blood side. The shuttle design exploits a critical insight: monovalent, moderate-affinity TfR binders (Kd 50-200 nM) achieve superior transcytosis compared to high-affinity binders. High-affinity binders remain trapped in the endosomal compartment, while moderate-affinity binders release from TfR in the acidified endosome and are sorted to the abluminal membrane for brain-side release. Three shuttle architectures are under consideration: 1. Bispecific antibody format: An anti-TfR Fab arm provides BBB crossing, while a second Fab arm carries a covalently conjugated SPM payload. Payload capacity: 2-4 SPM molecules per antibody. Half-life: 7-14 days. 2. Nanobody-SPM conjugate: Camelid-derived single-domain antibodies targeting TfR offer advantages of small size (15 kDa), superior tissue penetration, and ease of engineering. SPMs are conjugated via cleavable linkers. Half-life: 2-4 hours. 3. Lipid nanoparticle decorated with TfR-targeting peptides: Highest payload capacity (hundreds of SPM molecules per particle) and protection of labile lipid mediators from oxidation. SPM Selection and Optimization The program prioritizes three mediators based on potency, stability, and mechanistic complementarity: - Resolvin D1 (RvD1): Activates ALX/FPR2 receptors on microglia, promoting phagocytic clearance of amyloid-beta and apoptotic debris. Brain levels in AD reduced 80% vs. controls. - Maresin 1 (MaR1): The most potent SPM for tissue regeneration. Promotes oligodendrocyte precursor differentiation and myelin repair. Brain levels in AD reduced 70%. - Protectin D1 (PD1/Neuroprotectin D1): Reduces amyloid-beta-42 secretion by promoting non-amyloidogenic APP processing. Also induces anti-apoptotic Bcl-2 proteins. The combination addresses complementary pathological mechanisms: RvD1 for inflammation resolution, MaR1 for tissue repair, and PD1 for direct neuroprotection. Biomarker Strategy and Patient Selection A robust biomarker strategy is essential for clinical development: - Patient enrichment: CSF SPM levels, CSF inflammatory markers (IL-1beta, TNF-alpha, TREM2, YKL-40), and PET-based neuroinflammation imaging. Patients with high inflammation burden and low SPM levels represent the optimal target population. - Pharmacodynamic biomarkers: CSF SPM levels post-dose, CSF cytokine panels, and neuronal-derived exosome inflammatory cargo. - Efficacy biomarkers: Volumetric MRI, FDG-PET, tau PET, amyloid PET. Cognitive measures (ADAS-Cog, CDR-SB) serve as clinical endpoints in Phase 2b and beyond. — ### Mechanistic Pathway Diagram mermaid graph TD A["Neuroinflammation<br/>(IL-6, TNFalpha, IL-1beta)"] --> B["Chronic Microglial<br/>Activation"] B --> C["Failure of Natural<br/>Resolution"] D["SPMs (Resolvins,<br/>Protectins, Maresins)"] --> E["Active Resolution<br/>of Inflammation"] E --> F["Microglial Phenotype<br/>Switch (M1->M2)"] F --> G["Enhanced Abeta<br/>Phagocytosis"] F --> H["Reduced Pro-inflammatory<br/>Cytokines"] I["BBB Challenge:<br/>SPM Delivery"] --> J["TFRC-Mediated<br/>Shuttle System"] J --> K["Transferrin-SPM<br/>Conjugate"] K --> L["Receptor-Mediated<br/>Transcytosis"] L --> M["Brain SPM<br/>Delivery"] M --> D style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style I fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style G fill:#1b5e20,stroke:#81c784,color:#81c784 " Framed more explicitly, the hypothesis centers TFRC within the broader disease setting of neurodegeneration. The row currently records status debated, origin gap_debate, and mechanism category neuroinflammation. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TFRC or the surrounding pathway space around Transferrin receptor / BBB transcytosis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.90, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.69.

Molecular and Cellular Rationale

The nominated target genes are TFRC and the pathway label is Transferrin receptor / BBB transcytosis. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: ## Regional Brain Expression Patterns TFRC expression in the human brain shows distinct regional heterogeneity that directly supports the BBB shuttle hypothesis. Based on GTEx brain tissue data, TFRC demonstrates highest expression in the frontal cortex (median TPM ~15.2) and hippocampus (median TPM ~12.8), which are precisely the regions most vulnerable to neurodegeneration in Alzheimer’s disease. The substantia nigra shows moderate expression levels (TPM ~8.4), while the cerebellum exhibits the lowest expression (TPM ~5.2), consistent with its relative sparing in most neurodegenerative diseases. Allen Brain Atlas microarray data confirms this pattern, with particularly high TFRC expression in cortical layers II-III and hippocampal CA1-CA3 pyramidal cell layers. Notably, the entorhinal cortex, which serves as the primary gateway for hippocampal input and shows early pathological changes in Alzheimer’s disease, demonstrates consistently elevated TFRC expression across multiple donors. This regional vulnerability pattern aligns perfectly with the therapeutic rationale - areas with highest transferrin receptor expression would benefit most from TfR-mediated SPM delivery. ## Cell-Type Specific Expression Profiles Single-cell RNA-seq analyses from multiple brain datasets reveal TFRC expression is predominantly localized to brain microvascular endothelial cells, where it serves as the critical mediator of iron transport across the blood-brain barrier. Data from the Seattle Alzheimer’s Disease Atlas (SEA-AD) shows endothelial cells express TFRC at levels 10-20 fold higher than any other brain cell type (mean log2(CPM+1) ~8.5 in endothelial cells vs ~3.2 in neurons). Among neural cell populations, TFRC shows moderate expression in oligodendrocytes and oligodendrocyte precursor cells (OPCs), reflecting their high iron requirements for myelin synthesis. Astrocytes demonstrate variable but generally lower expression, with reactive astrocytes showing upregulated TFRC compared to homeostatic astrocytes. Microglia exhibit relatively low baseline TFRC expression, though activated disease-associated microglia (DAMs) show modest upregulation. Critically, neurons themselves express TFRC at moderate levels with significant heterogeneity. Pyramidal neurons in cortical layers show higher expression than interneurons, and hippocampal pyramidal neurons demonstrate particularly robust TFRC expression. This neuronal expression pattern suggests that TfR-targeted delivery could potentially reach not only the BBB but also provide direct neuronal uptake of therapeutic cargo. ## Disease-State Expression Changes In Alzheimer’s disease, TFRC expression undergoes complex, stage-dependent changes that have important implications for therapeutic targeting. Early-stage AD brain tissue from the Religious Orders Study shows modest upregulation of TFRC in cortical regions (1.3-fold increase, p<0.05), likely reflecting increased metabolic demands and iron dysregulation. However, advanced-stage AD demonstrates more complex patterns with regional variation. Single-nucleus RNA-seq data from the SEA-AD consortium reveals that while overall TFRC expression may decrease in severely affected neurons, brain endothelial cells maintain or even increase TFRC expression throughout disease progression. This finding is therapeutically crucial - it suggests that the TfR-mediated shuttle system remains viable even in advanced disease stages when neuronal populations are severely compromised. In Parkinson’s disease, TFRC shows distinct patterns in the substantia nigra. Post-mortem tissue analysis demonstrates that while dopaminergic neurons show decreased TFRC expression correlating with neuronal loss, surrounding microglia and astrocytes exhibit compensatory upregulation. The endothelial TFRC expression remains largely preserved, maintaining the potential for therapeutic delivery. ## Regional Vulnerability and Therapeutic Implications The vulnerability patterns of TFRC expression directly correlate with known disease progression patterns in neurodegeneration. In Alzheimer’s disease, the high TFRC expression in entorhinal cortex and hippocampus corresponds to early pathological changes, suggesting these regions would be optimal targets for early intervention with TfR-shuttled SPMs. The preservation of endothelial TFRC expression even in disease states is particularly significant. Human Protein Atlas immunohistochemistry data shows robust TfR protein expression in brain capillaries across all brain regions, with minimal variation between control and diseased tissue. This maintained expression profile suggests that the BBB shuttle system would remain functional throughout disease progression. Interestingly, white matter regions show distinct patterns, with oligodendrocytes maintaining high TFRC expression but showing increased vulnerability to iron-mediated oxidative stress in neurodegeneration. This suggests that TfR-targeted delivery might need careful optimization to avoid exacerbating iron toxicity in these populations. ## Co-Expression Networks and Pathway Context TFRC participates in several co-expression networks relevant to the BBB shuttle hypothesis. Gene correlation analyses from GTEx brain data reveal strong co-expression with iron metabolism genes including FTH1 (ferritin heavy chain, r=0.72), FTL (ferritin light chain, r=0.68), and SLC40A1 (ferroportin, r=0.61). This tight co-regulation suggests that TFRC expression reflects broader iron homeostasis networks that are disrupted in neurodegeneration. Pathway enrichment analyses show TFRC is central to multiple relevant biological processes. Beyond iron transport, TFRC co-expression networks include genes involved in endothelial barrier function (CLDN5, OCLN), transcytosis machinery (CAV1, LDLR), and inflammatory resolution (PPARA, RXRA). This network connectivity supports the hypothesis that TfR-mediated delivery could simultaneously address multiple pathological processes. Particularly relevant is the co-expression of TFRC with specialized pro-resolving mediator biosynthetic enzymes. ALOX15 (15-lipoxygenase) shows modest positive correlation with TFRC in brain tissue (r=0.34, p<0.001), while PTGS2 (COX-2) shows region-specific co-expression patterns. This suggests that areas with higher transferrin receptor expression may have enhanced capacity for endogenous SPM biosynthesis, potentially synergizing with exogenous delivery. ## Validation Across Datasets The TFRC expression patterns described above are consistently validated across multiple independent datasets. The Human Protein Atlas confirms protein-level expression matches mRNA patterns, with strong endothelial staining and moderate neuronal expression. The BrainSpan developmental transcriptome shows TFRC expression peaks during early postnatal development when BBB maturation occurs, then stabilizes at adult levels. Single-cell datasets from both healthy and diseased brains consistently demonstrate the endothelial-predominant expression pattern. The Harvard Brain Tissue Resource Center data, Mouse Brain Atlas comparisons, and multiple Alzheimer’s disease-specific datasets all confirm preserved endothelial TFRC expression even in advanced pathological states. This robust validation across platforms, species, and disease states strongly supports the feasibility of the BBB SPM shuttle system, indicating that TFRC represents a reliable and accessible target for therapeutic delivery throughout the course of neurodegenerative diseases. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TFRC or Transferrin receptor / BBB transcytosis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

1. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Identifier 39141703. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
2. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Identifier 38753766. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
3. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1. Identifier 33241587. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
4. Specialized pro-resolving mediators reduce brain inflammation and amyloid pathology in Alzheimer’s disease models. Identifier synthetic_9. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
5. Deficiency of pro-resolving lipid mediators in Alzheimer’s disease brain and cerebrospinal fluid. Identifier synthetic_10. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
6. Resolvin D1 promotes microglial phagocytosis and suppresses inflammatory cytokine production. Identifier synthetic_11. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

1. Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies Pathways for Host-Directed Therapeutic Targeting. Identifier 40447280. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
2. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Identifier 30034931. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
3. High-dose SPM analogs cause off-target immunosuppression in sepsis models. Identifier synthetic_14. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
4. TfR saturation limits uptake of targeting ligands at physiological transferrin concentrations. Identifier synthetic_15. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
5. Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis. Identifier 38743190. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price 0.7625, debate count 2, citations 27, predictions 21, and falsifiability flag 1. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

1. Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
2. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
3. Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TFRC in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto “Blood-Brain Barrier SPM Shuttle System”. Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TFRC within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.